Sentence examples for Adverse pathology from inspiring English sources

Numerous definitions of adverse pathology at radical prostatectomy (RP) have been proposed and implemented for both research and clinical care, and there is tremendous variation in the specific criteria used to define adverse pathology in these settings.

Several predictive nomograms and novel genomic markers have been developed to estimate the risk of adverse pathology in men eligible for active surveillance (AS).

Given the current landscape in which magnetic resonance imaging criteria and biomarker cutoffs are validated for disparate adverse pathology definitions, we sought to identify which of these is most closely tied to biochemical recurrence (BCR) after RP.

The presence of a tertiary Gleason grade (TGG) pattern in radical prostatectomy (RP) specimens has been described as associated with adverse pathology and a higher biochemical recurrence (BCR) rate after RP.

A 17-gene biopsy-based reverse transcription polymerase chain reaction assay, which provides a Genomic Prostate Score (GPS scale 0 100), has been validated as an independent predictor of adverse pathology and biochemical recurrence after radical prostatectomy (RP) in men with low- and intermediate-risk prostate cancer (PCa).

In post-meeting discussions, several Panel members suggested that adverse pathology should identify patients with lower nodal burden requiring radiotherapy.

However, our results suggest that local expression of TGF-β1, unlike systemic expression, is not therapeutic due to adverse pathologies associated with elevated intra-articular TGF-β1 expression.

The results suggest that elevated TGF-β1 expression confers adverse joint pathology including an increase in cartilage matrix degradation without stimulating new matrix synthesis.

Post-mastectomy radiotherapy was considered indicated by almost all Panel members for patients with four or more positive nodes, while the majority would not advise post-mastectomy irradiation for those with one to three positive nodes, except in the presence of adverse tumour pathology.

Thus, multiple immunosuppressive programs have evolved to eliminate the adverse autoimmune pathologies, such as rheumatoid arthritis, that are associated with over-activation of these M1 responses [ 80]; unfortunately, many of these immunosuppressive programs are usurped by developing cancers.

This slow degradation likely accounts for the lack of adverse clinical and pathology effects after 12 weeks.